Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was...
Main Authors: | Hirokazu Takahashi, Takaomi Kessoku, Miwa Kawanaka, Michihiro Nonaka, Hideyuki Hyogo, Hideki Fujii, Tomoaki Nakajima, Kento Imajo, Kenichi Tanaka, Yoshihito Kubotsu, Hiroshi Isoda, Satoshi Oeda, Osamu Kurai, Masato Yoneda, Masafumi Ono, Yoichiro Kitajima, Ryo Tajiri, Ayako Takamori, Atsushi Kawaguchi, Shinichi Aishima, Masayoshi Kage, Atsushi Nakajima, Yuichiro Eguchi, Keizo Anzai |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health/LWW
2022-01-01
|
Series: | Hepatology Communications |
Online Access: | https://doi.org/10.1002/hep4.1696 |
Similar Items
-
Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
by: Hirokazu Takahashi, et al.
Published: (2022-09-01) -
A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
by: Takashi Kobayashi, et al.
Published: (2022-10-01) -
Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
by: Yasushi Honda, et al.
Published: (2020-06-01) -
Identification of differentially methylated regions associated with both liver fibrosis and hepatocellular carcinoma
by: Suguru Kurokawa, et al.
Published: (2024-02-01) -
Comparison of long‐term prognosis between non‐obese and obese patients with non‐alcoholic fatty liver disease
by: Michihiro Iwaki, et al.
Published: (2022-10-01)